Analysis of progression-free survival data using a discrete time survival model that incorporates measurements with and without diagnostic error

Clinical Trials

Volumn 7, Issue 6, 2010, Pages 634-642

  Hunsberger, Sally ^a   Albert, Paul S ^b   Dodd, Lori ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYZER; ARTICLE; CANCER SURVIVAL; DATA ANALYSIS; DIAGNOSTIC ERROR; DISCRETE TIME SURVIVAL MODEL; INFORMATION PROCESSING; KIDNEY CANCER; MEASUREMENT ERROR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; SIMULATION;

ALGORITHMS; COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC ERRORS; DISEASE PROGRESSION; HUMANS; MARYLAND; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASMS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 78650364861     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774510384887     Document Type: Article

References (13)

1. Chakravarty A., Sridhara R. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Method Med Res 2008 ; 17: 515-18.
2. FDA. Guidance to industry clinical trial endpoints for the approval of cancer drugs and biologics. Available at: http://www.fda.gov/cder/guidance/ 6592dft.htm (accessed 2007 ).
3. Meier AS, Richardson BA, Hughes JP Discrete proportional hazards models for mismeasured outcomes. Biometrics 2003 ; 59: 947-54.
4. Magaret AS Incorporating validation subsets into discrete proportional hazards models for mismeasured outcomes. Stat Med 2008 ; 27: 5456-70.
5. Kalbfleisch JD, Prentice RL The Statistical Analysis of Failure Time Data. John Wiley & Sons, New York, 1980.
6. Bross I. Misclassification in 2x2 tables. Biometrics 1954 ; 10: 478-86.
7. Cochran WG Errors of measurement in statistics. Technometrics 1968 ; 10: 637-66.
8. Tenenbein A. A double sampling scheme for estimating from binomial data with misclassifications. J Am Stat Assoc 1970 ; 65: 1350-61.
9. Palmgren J. Precision of double sampling estimators for comparing two probabilites. Biometrika 1987 ; 74: 687-94.
10. Aptech Systems. Version 3.2 Kent. Gauss Systems Washington, 1995.
11. Qu Y., Tan M., Kutner MH Random effects models in latent class analysis for evaluating accuracy of diagnostic tests. Biometrics 1996 ; 52: 797-810.
12. Abramowitz M., Stegun I. Handbook of Mathematical Functions. Dover, New York, 1974.
13. Yang JC, Haworth L., Sherry JM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349: 427-34.